1. Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies.
- Author
-
Voges B, Vallbracht S, Zimmer G, Bossow S, Neubert WJ, Richter K, Hobeika E, Herrler G, and Ehl S
- Subjects
- Animals, Antibodies immunology, Mice, Mice, Inbred BALB C, Respiratory Syncytial Virus Infections pathology, Solubility, T-Lymphocytes drug effects, Viral Fusion Proteins genetics, Viral Fusion Proteins immunology, Genetic Engineering, Respiratory Syncytial Virus Infections immunology, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Viruses immunology, Sendai virus genetics, Sendai virus immunology, T-Lymphocytes immunology
- Abstract
Respiratory syncytial virus (RSV) causes severe respiratory disease in infants and a vaccine is highly desirable. The fusion (F) protein of RSV is an important vaccine target, but the contribution of F-specific T cells to successful vaccination remains unclear. We studied the immune response to vaccination of mice with a recombinant Sendai virus expressing RSV F (rSeV F). rSeV F induced protective neutralizing antibody and RSV F-specific CTL responses. T cell immunity was stronger than that induced by recombinant vaccinia virus (rVV F), a well characterized reference vector. Vaccination of antibody-deficient mice showed that vaccine-induced RSV F-specific T cells were sufficient for protective immunity. rSeV F induced T cell immunity in the presence of neutralizing antibodies, which did not impair the vaccine response. Although the F protein only contains a subdominant CTL epitope, vaccination with rSeV F is sufficient to induce protective T cell immunity against RSV in mice.
- Published
- 2007
- Full Text
- View/download PDF